Evercore ISI Group Rates ICON Public (ICLR) buy

Analyst Ross Muken of Evercore ISI reiterated a buy rating on ICON Public Limited Company, setting a price target of $180 on June 25, 2026, a 5.97% upside from the current price.

By EarningsIQ Research Desk · Published Jun 25, 2026, 10:00 AM EDT · Updated Jun 29, 2026, 11:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Evercore ISI Group rated ICON Public Limited Company ($ICLR) "buy" with a $180 price target on June 25, 2026.

Since the rating, $ICLR is up 7.5% after 1 week, up 4.9% after 1 month and up 5.7% to date (from the $160.96 close on Jun 25, 2026).

ICLR ICON Public Limited Company

$170.18 -9.80% year to date

Daily close · Oct 16, 2026

Key Points

Evercore ISI analyst Ross Muken reiterated a buy rating on ICON Public Limited Company (NasdaqGS: ICLR) with an $180 price target on June 25, 2026.
Evercore ISI Group's $180 price target implies 5.97% upside from ICON Public Limited Company's ($ICLR) current $169.86 share price.
Shares of ICON changed hands around $169.86, trading near its 50-day moving average of $167.30 and above its 200-day average of $147.20.
A total of 16 analysts currently follow the clinical research firm, sending the consensus recommendation to a buy with a mean target of $185.25.

Get $ICLR trade alerts by text

We text you when insiders, Congress or big funds trade $ICLR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ICON Public Limited Company alert may contain errors. Disclosures

Evercore ISI Maintains Stance on ICON

Evercore ISI Group has reaffirmed its positive stance on clinical research provider ICON Public Limited Company (NasdaqGS: ICLR). On June 25, 2026, analyst Ross Muken reiterated a buy rating on the shares, holding the price target steady at $180. The update comes as part of a wider wave of summer analyst commentary surrounding the Dublin-based medical research firm.

Analyst rating track record

Evercore ISI Group vs. the S&P 500

YTD return +13.45% hypothetical

All-time return +26.45% S&P 500 +26.41%

vs. S&P 500 +0.04% ahead of the index

Hypothetical returns from Evercore ISI Group's disclosed trades, not real profit or advice. How we model this.

Recent Analyst Moves and Price Targets

Wall Street firms have kept busy updating their outlooks on ICLR through the summer and fall. On September 18, 2026, Citigroup maintained its neutral rating while adjusting its price target to $175 from $140. Earlier in the summer on July 31, 2026, Truist Securities reiterated a buy rating with a $209 target after having upgraded the stock to buy on June 30 with a $207 target. Mizuho also kept an outperform rating on June 26, 2026, raising its target to $190. BMO Capital maintained an outperform rating with a $187 target on June 25, 2026, while Barclays kept an equal-weight rating with a $175 target on the same day. Overall, the stock carries a consensus buy recommendation from 16 analysts with a mean price target of $185.25.

Market Standing and Valuation

Shares of ICON traded hands at $169.86. The company holds a market capitalization of roughly $13.08 billion and a forward P/E ratio of 14.37, while its trailing P/E sits at 256.89 due to lower recent earnings per share. The stock moves within a 52-week range of $66.57 to $203.91, resting just above its 50-day moving average of $167.30 and comfortably above its 200-day moving average of $147.20.

What ICON Public Limited Does

ICON is a clinical research organization that provides outsourced development and commercialization services for pharmaceutical, biotechnology, and medical device companies worldwide. The business handles everything from compound selection and early Phase I trials to late-stage Phase IV studies, laboratory testing, and post-market safety monitoring. Headquartered in Dublin, Ireland, the firm employs over 40,000 people to support complex medical trials and public health organizations.

Outlook Ahead for ICLR

Investors will look toward the company's next financial update scheduled for October 21, 2026, to gauge revenue growth and profit margins. Analyst target adjustments and continued research updates will remain focal points for market participants tracking the clinical research sector.

12-month forecast